Ovarian Cancer Clinical Trial

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Summary

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies.

The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion) and Part 2 (dose expansion).

View Eligibility Criteria

Eligibility Criteria

General Inclusion Criteria:

Female participants with advanced or metastatic HR+/HER2- breast cancer will be required to have ovarian function suppression using gonadotropin hormone-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Adequate organ function.

Part 1 (Dose Escalation) Inclusion Criteria:

Participants with histologically or cytologically confirmed advanced or metastatic solid tumors potentially associated with CDK2 dependency including HR+/HER2- breast cancer, platinum refractory or resistant serous ovarian, fallopian tube, primary peritoneal cancer (PROC), small cell lung cancer (SCLC), and others.
Participants should have received prior available systemic therapy for their condition and should be refractory to or intolerant of standard-of-care therapies.
Participants with advanced solid tumors must have measurable disease per RECIST 1.1.

Part 1 (Safety Expansion) Inclusion Criteria:

Participants with advanced or metastatic HR+/HER2- breast cancer, PROC, or SCLC.

Part 2 (Dose Expansion) Inclusion Criteria:

Participants with selected advanced or metastatic HR+/HER2- breast cancer, PROC, SCLC, or advanced solid tumors with a specific gene mutation based on standard-of-care testing.

General Exclusion Criteria:

Prior therapy selectively targeting CDK2 inhibition. Prior CDK4/6 inhibitor therapy is permitted and required in local regions where it is approved and available.
Known leptomeningeal disease or uncontrolled, untreated brain metastasis. Participants with a history of treated central nervous system (CNS) metastases may be eligible if they meet additional criteria.
Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
Uncontrolled diabetes.
Infection requiring systemic antibacterial, antifungal, or antiviral therapy antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection.
History of hepatitis B or active hepatitis C infection.
Any major surgical procedure ≤ 28 days before the first dose of study treatment(s).
Prior allogeneic stem cell transplantation, or organ transplantation.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

108

Study ID:

NCT06257264

Recruitment Status:

Recruiting

Sponsor:

BeiGene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Titan Health Partners Llc Dba Astera Cancer Care
East Brunswick New Jersey, 08816, United States
Mary Crowley Cancer Research
Dallas Texas, 75230, United States
Blacktown Cancer and Haematology Centre
Blacktown New South Wales, 2148, Australia
Genesiscare North Shore
St Leonards New South Wales, 2065, Australia

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

108

Study ID:

NCT06257264

Recruitment Status:

Recruiting

Sponsor:


BeiGene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.